Incyte on a Roll with Two FDA Wins in Two Days

Incyte announced today that the U.S. Food and Drug Administration (FDA) approved its Jakafi (ruxolitinib) to treat chronic graft-versus-host disease (GVHD).

The news comes just a day after the regulator gave its atopic dermatitis cream, Opzelura (ruxolinitib), the green light for short-term and non-continuous chronic treatment of mild to moderate AD.